Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
about
Maraviroc: a review of its use in HIV infection and beyondOnce-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.HIV-1 co-receptor tropism and disease progression in children and young adults with perinatally acquired HIV-1 infection. The HICCUP Study.Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.Preclinical discovery and development of maraviroc for the treatment of HIV.Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.Moving forward with treatment options for HIV-infected children.Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.Off-label use of maraviroc in clinical practice.Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
P2860
Q26778504-2EC3CB5D-56AC-4A9F-AC00-CA53E8B12725Q36868170-F06515E8-6824-44DD-9820-D0B43F7BDF5BQ37098369-F274BAE8-E64E-411D-BEA0-2A0483FF54E4Q38970509-E50A7BF5-0CF4-44BC-92CC-7D32B32A4F66Q39366403-FD712F2D-39A2-4396-B38F-C7B3C35556B4Q39556338-5EC2B596-A0C3-424F-B52C-D7C8FC8A76E3Q39696831-CC97B4A2-5C2C-4F07-8F65-E96050AFE2FFQ40063042-6B0C78F9-AFF1-4FD0-BBF1-82AE89C46837Q41989387-6426EAB2-2CDC-4109-8C4B-00A45BF8FAEAQ42654565-2D53CC74-9411-422B-9E40-DA756D322DBFQ42696471-5AB67373-2003-46E4-B246-BCF2DD9FC350Q45170011-225FADDB-637E-417A-A406-504F48B9BF2E
P2860
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of maravir ...... ts with HIV-1: 5-year findings
@en
Efficacy and safety of maravir ...... s with HIV-1: 5-year findings.
@nl
type
label
Efficacy and safety of maravir ...... ts with HIV-1: 5-year findings
@en
Efficacy and safety of maravir ...... s with HIV-1: 5-year findings.
@nl
prefLabel
Efficacy and safety of maravir ...... ts with HIV-1: 5-year findings
@en
Efficacy and safety of maravir ...... s with HIV-1: 5-year findings.
@nl
P2093
P2860
P1433
P1476
Efficacy and safety of maravir ...... ts with HIV-1: 5-year findings
@en
P2093
David A Cooper
Edwin Dejesus
Elna van Der Ryst
Geoffrey Mukwaya
Jayvant Heera
Mariette Botes
Michael Saag
Nathan Clumeck
Prudence Ive
Robert Burnside
P2860
P304
P356
10.1097/QAD.0000000000000131
P407
P577
2014-03-01T00:00:00Z